Micafungin Accord (Micafungin)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, which is required to build β‑(1,3)‑D‑glucan, an essential polymer of the fungal cell wall. Inhibiting this pathway weakens the wall, leading to osmotic instability and fungal cell death, while human cells are largely unaffected because they do not contain this polymer.

The specific dose and duration of Micafungin Accord are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and the indication being treated. Healthcare professionals follow approved labeling and clinical guidelines to set an appropriate regimen.

Safety data for micafungin in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To request Micafungin Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to membrane sterols. Echinocandins, including micafungin, are generally well‑tolerated, have fewer drug‑drug interactions, and are effective against many azole‑resistant Candida strains, making them a valuable alternative in resistant or severe infections.

Micafungin Accord should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures the product’s stability and potency until administration.

Micafungin Accord is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central line, typically over a period of 30‑60 minutes, depending on the prescribed dose and clinical protocol.

The most serious adverse events include severe hepatic injury, anaphylactic or severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and profound hypotension during infusion. Patients should be monitored closely for signs of liver dysfunction, allergic reactions, and hemodynamic changes, especially during the initial infusion.

Micafungin Accord is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those who have experienced severe infusion‑related reactions to echinocandins.